BAY 58–2667, a soluble guanylate cyclase activator, improves cardiopulmonary haemodynamics in acute decompensated heart failure and has a favourable safety profile
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2210
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
BAY 58–2667, a soluble guanylate cyclase activator, improves cardiopulmonary haemodynamics in acute decompensated heart failure and has a favourable safety profile ; volume:7 ; number:1 ; day:25 ; month:7 ; year:2007 ; pages:1-2 ; date:7.2007
BMC pharmacology ; 7, Heft 1 (25.7.2007), 1-2, 7.2007
- Urheber
-
Lapp, Harald
Mitrovic, Veselin
Franz, Norbert
Heuer, Hubertus
Buerke, Michael
Wolfertz, Judith
Mück, Wolfgang
Unger, Sigrun
Wensing, Georg
Frey, Reiner
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/1471-2210-7-S1-S9
- URN
-
urn:nbn:de:101:1-2019110223230428594788
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:24 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Lapp, Harald
- Mitrovic, Veselin
- Franz, Norbert
- Heuer, Hubertus
- Buerke, Michael
- Wolfertz, Judith
- Mück, Wolfgang
- Unger, Sigrun
- Wensing, Georg
- Frey, Reiner
- SpringerLink (Online service)
Ähnliche Objekte (12)
BAY 58–2667, a soluble guanylate cyclase activator, has a favourable safety profile and reduces peripheral vascular resistance in healthy male volunteers
Structural studies of soluble guanylate cyclase
Binding of [3H]BAY 58-2667 to purified bovine lung soluble guanylate cyclase by scintillation proximity assay
Antiplatelet effects of aspirin are not affected by the soluble guanylate cyclase activator cinaciguat (BAY 58-2667)
Molecular steps in soluble guanylate cyclase activation
Lessons from soluble guanylate cyclase alpha1 knockouts
The role of soluble guanylate cyclase in metabolism
The soluble guanylate cyclase activator BAY 58-2667 protects against morbidity and mortality in endotoxic shock by recoupling organ systems
Stimulation of soluble guanylate cyclase reduces experimental dermal fibrosis
Role of soluble guanylate cyclase in progressive renal fibrosis
Co-activation of soluble and particulate guanylate cyclase by BAY 58-2667 and BNP enhances cardiorenal function in experimental heart failure
BAY 63–2521, an oral soluble guanylate cyclase stimulator, has a favourable safety profile and decreases peripheral vascular resistance in healthy male volunteers
BAY 58–2667, a soluble guanylate cyclase activator, has a favourable safety profile and reduces peripheral vascular resistance in healthy male volunteers
Structural studies of soluble guanylate cyclase
Binding of [3H]BAY 58-2667 to purified bovine lung soluble guanylate cyclase by scintillation proximity assay
Antiplatelet effects of aspirin are not affected by the soluble guanylate cyclase activator cinaciguat (BAY 58-2667)
Molecular steps in soluble guanylate cyclase activation
Lessons from soluble guanylate cyclase alpha1 knockouts
The role of soluble guanylate cyclase in metabolism
The soluble guanylate cyclase activator BAY 58-2667 protects against morbidity and mortality in endotoxic shock by recoupling organ systems
Stimulation of soluble guanylate cyclase reduces experimental dermal fibrosis
Role of soluble guanylate cyclase in progressive renal fibrosis
Co-activation of soluble and particulate guanylate cyclase by BAY 58-2667 and BNP enhances cardiorenal function in experimental heart failure
BAY 63–2521, an oral soluble guanylate cyclase stimulator, has a favourable safety profile and decreases peripheral vascular resistance in healthy male volunteers
BAY 58–2667, a soluble guanylate cyclase activator, has a favourable safety profile and reduces peripheral vascular resistance in healthy male volunteers
Structural studies of soluble guanylate cyclase
Binding of [3H]BAY 58-2667 to purified bovine lung soluble guanylate cyclase by scintillation proximity assay
Antiplatelet effects of aspirin are not affected by the soluble guanylate cyclase activator cinaciguat (BAY 58-2667)
Molecular steps in soluble guanylate cyclase activation
Lessons from soluble guanylate cyclase alpha1 knockouts
The role of soluble guanylate cyclase in metabolism
The soluble guanylate cyclase activator BAY 58-2667 protects against morbidity and mortality in endotoxic shock by recoupling organ systems
Stimulation of soluble guanylate cyclase reduces experimental dermal fibrosis
Role of soluble guanylate cyclase in progressive renal fibrosis
Co-activation of soluble and particulate guanylate cyclase by BAY 58-2667 and BNP enhances cardiorenal function in experimental heart failure